Concizumab C 40 mg/mL PDS290

DRUG3 trials

Sponsors

Novo Nordisk A/S

Conditions

Haemophilia A or B with or without inhibitorshaemophilia A (HA) with inhibitors and haemophilia B (HB) with inhibitorshaemophilia A (HA) without inhibitors and haemophilia B (HB) without inhibitors

Phase 3

Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B with inhibitors

Active, not recruitingCTIS2023-506832-33-00

Novo Nordisk A/Shaemophilia A (HA) with inhibitors and haemophilia B (HB) with inhibitors

Start: 2019-11-06Target: 43Updated: 2025-09-08

Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B without inhibitors

Active, not recruitingCTIS2023-506831-13-00

Novo Nordisk A/Shaemophilia A (HA) without inhibitors and haemophilia B (HB) without inhibitors

Start: 2020-01-15Target: 41Updated: 2025-09-29

Open-label study investigating efficacy, safety and pharmacokinetics of concizumab prophylaxis in children below 12 years with haemophilia A or B with or without inhibitors

Active, not recruitingCTIS2023-506925-13-00

Novo Nordisk A/SHaemophilia A or B with or without inhibitors

Start: 2022-07-01Target: 44Updated: 2025-10-07